Condition
Platinum-Sensitive Lung Small Cell Carcinoma
Total Trials
4
Recruiting
0
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (3)
Trial Status
Active Not Recruiting3
Withdrawn1
Clinical Trials (4)
Showing 4 of 4 trials
NCT05353439Phase 1Active Not Recruiting
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
NCT03896503Phase 2Active Not Recruiting
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs
NCT04607954Phase 2Active Not Recruiting
Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
NCT05572476Phase 2Withdrawn
Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
Showing all 4 trials